Literature DB >> 29788331

Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.

Anthony J Garcia-Prats1, Heather R Draper1, Heather Finlayson2, Jana Winckler1, André Burger3, Barend Fourie2, Stephanie Thee4, Anneke C Hesseling1, H Simon Schaaf1.   

Abstract

Safety concerns persist for long-term pediatric fluoroquinolone use. Seventy children (median age, 2.1 years) treated with levofloxacin 10-20 mg/kg once daily for multidrug-resistant tuberculosis (median observation time, 11.8 months) had few musculoskeletal events, no levofloxacin-attributed serious adverse events, and no Fridericia-corrected QT interval >450 ms. Long-term levofloxacin was safe and well tolerated.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29788331      PMCID： PMC6233673          DOI： 10.1093/cid/ciy416

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  11 in total

1.  Effects of three fluoroquinolones on QT interval in healthy adults after single doses.

Authors:  Gary J Noel; Jaya Natarajan; Shuchean Chien; Thomas L Hunt; Daniel B Goodman; Robert Abels
Journal:  Clin Pharmacol Ther       Date:  2003-04       Impact factor: 6.875

2.  Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.

Authors:  Gary J Noel; Daniel B Goodman; Shuchean Chien; Bhavna Solanki; Mukund Padmanabhan; Jaya Natarajan
Journal:  J Clin Pharmacol       Date:  2004-05       Impact factor: 3.126

Review 3.  QTc prolongation and treatment of multidrug-resistant tuberculosis.

Authors:  E Harausz; H Cox; M Rich; C D Mitnick; P Zimetbaum; J Furin
Journal:  Int J Tuberc Lung Dis       Date:  2015-04       Impact factor: 2.373

4.  Sleep disturbance in children treated with ofloxacin.

Authors:  C Upton
Journal:  BMJ       Date:  1994-11-26

Review 5.  Quinolone arthropathy in animals versus children.

Authors:  J E Burkhardt; J N Walterspiel; U B Schaad
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

6.  The use of systemic fluoroquinolones.

Authors: 
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

Review 7.  Fluoroquinolones for the treatment of tuberculosis in children.

Authors:  S Thee; A J Garcia-Prats; P R Donald; A C Hesseling; H S Schaaf
Journal:  Tuberculosis (Edinb)       Date:  2015-02-14       Impact factor: 3.131

8.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

Authors:  J Kang; L Wang; X L Chen; D J Triggle; D Rampe
Journal:  Mol Pharmacol       Date:  2001-01       Impact factor: 4.436

9.  Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin.

Authors:  Chuen L Yee; Ciaran Duffy; Peter G Gerbino; Scott Stryker; Gary J Noel
Journal:  Pediatr Infect Dis J       Date:  2002-06       Impact factor: 2.129

10.  Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anthony J Garcia-Prats; Heather R Draper; Lubbe Wiesner; Jana Winckler; Stephanie Thee; Kelly E Dooley; Rada M Savic; Helen M McIlleron; H Simon Schaaf; Anneke C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191
View more
  4 in total

1.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

2.  Clinical standards for the dosing and management of TB drugs.

Authors:  J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

3.  Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).

Authors:  James A Seddon; Anthony J Garcia-Prats; Susan E Purchase; Muhammad Osman; Anne-Marie Demers; Graeme Hoddinott; Angela M Crook; Ellen Owen-Powell; Margaret J Thomason; Anna Turkova; Diana M Gibb; Lee Fairlie; Neil Martinson; H Simon Schaaf; Anneke C Hesseling
Journal:  Trials       Date:  2018-12-20       Impact factor: 2.279

4.  Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.

Authors:  Ji-Gan Wang; Hai-Rong Cui; Yi-Sen Hu; Hua-Bo Tang
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.